These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

459 related articles for article (PubMed ID: 31474998)

  • 1. Checkpoint Inhibition May Trigger the Rare Variant of Anti-LAD-1 IgG-Positive, Anti-BP180 NC16A IgG-Negative Bullous Pemphigoid.
    Sadik CD; Langan EA; Grätz V; Zillikens D; Terheyden P
    Front Immunol; 2019; 10():1934. PubMed ID: 31474998
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation of Serum Levels of IgE Autoantibodies Against BP180 With Bullous Pemphigoid Disease Activity.
    van Beek N; Lüttmann N; Huebner F; Recke A; Karl I; Schulze FS; Zillikens D; Schmidt E
    JAMA Dermatol; 2017 Jan; 153(1):30-38. PubMed ID: 27829102
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Normal human skin is superior to monkey oesophagus substrate for detection of circulating BP180-NC16A-specific IgG antibodies in bullous pemphigoid.
    Emtenani S; Yuan H; Lin C; Pan M; Hundt JE; Schmidt E; Komorowski L; Stanley JR; Hammers CM
    Br J Dermatol; 2019 May; 180(5):1099-1106. PubMed ID: 30315657
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and Immunological Profiles of 14 Patients With Bullous Pemphigoid Without IgG Autoantibodies to the BP180 NC16A Domain.
    Nakama K; Koga H; Ishii N; Ohata C; Hashimoto T; Nakama T
    JAMA Dermatol; 2018 Mar; 154(3):347-350. PubMed ID: 29299596
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of IgG antibodies to BP180 NC16a and C-terminal domains and LAD-1 in nivolumab-associated bullous pemphigoid.
    Matsui Y; Makino T; Ishii N; Hashimoto T; Shimizu T
    Eur J Dermatol; 2019 Oct; 29(5):554-555. PubMed ID: 31570332
    [No Abstract]   [Full Text] [Related]  

  • 6. Patients with bullous pemphigoid and linear IgA disease show a dual IgA and IgG autoimmune response to BP180.
    Kromminga A; Scheckenbach C; Georgi M; Hagel C; Arndt R; Christophers E; Bröcker EB; Zillikens D
    J Autoimmun; 2000 Nov; 15(3):293-300. PubMed ID: 11040070
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preferential Reactivity of Dipeptidyl Peptidase-IV Inhibitor-Associated Bullous Pemphigoid Autoantibodies to the Processed Extracellular Domains of BP180.
    Mai Y; Nishie W; Izumi K; Shimizu H
    Front Immunol; 2019; 10():1224. PubMed ID: 31191560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BPDAI and ABSIS correlate with serum anti-BP180 NC16A IgG but not with anti-BP230 IgG in patients with bullous pemphigoid.
    Daneshpazhooh M; Ghiasi M; Lajevardi V; Nasiri N; Balighi K; Teimourpour A; Khosravi H; Saeidi V; Mahmoudi H; Chams-Davatchi C
    Arch Dermatol Res; 2018 Apr; 310(3):255-259. PubMed ID: 29423547
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum levels of IgE anti-BP180 and anti-BP230 autoantibodies in patients with bullous pemphigoid.
    Ishiura N; Fujimoto M; Watanabe R; Nakashima H; Kuwano Y; Yazawa N; Echigo T; Okochi H; Tamaki K
    J Dermatol Sci; 2008 Feb; 49(2):153-61. PubMed ID: 17920818
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bullous pemphigoid induced by dipeptidyl peptidase-4 inhibitors. Eight cases with clinical and immunological characterization.
    García-Díez I; Ivars-Lleó M; López-Aventín D; Ishii N; Hashimoto T; Iranzo P; Pujol RM; España A; Herrero-Gonzalez JE
    Int J Dermatol; 2018 Jul; 57(7):810-816. PubMed ID: 29682739
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IgG4 and IgE are the major immunoglobulins targeting the NC16A domain of BP180 in Bullous pemphigoid: serum levels of these immunoglobulins reflect disease activity.
    Döpp R; Schmidt E; Chimanovitch I; Leverkus M; Bröcker EB; Zillikens D
    J Am Acad Dermatol; 2000 Apr; 42(4):577-83. PubMed ID: 10727301
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of a novel ELISA system for detection of anti-BP180 IgG and characterization of autoantibody profile in bullous pemphigoid patients.
    Mariotti F; Grosso F; Terracina M; Ruffelli M; Cordiali-Fei P; Sera F; Zambruno G; Mastrogiacomo A; Di Zenzo G
    Br J Dermatol; 2004 Nov; 151(5):1004-10. PubMed ID: 15541078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the combination of BP180-NC16a enzyme-linked immunosorbent assay and BP230 enzyme-linked immunosorbent assay in the diagnosis of bullous pemphigoid.
    Yang B; Wang C; Chen S; Chen X; Lu X; Tian H; Yu M; Zhang D; Shi Z; Zhou G; Zhang F
    Indian J Dermatol Venereol Leprol; 2012; 78(6):722-7. PubMed ID: 23075641
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Levels of anti-BP180 NC16A IgE do not correlate with severity of disease in the early stages of bullous pemphigoid.
    Bing L; Xiping Z; Li L; Jun P; Yi-Xia W; Min Y; Qing L; Qiu-Ning S; Hong-Zhong J; Ya-Gang Z
    Arch Dermatol Res; 2015 Nov; 307(9):849-54. PubMed ID: 26404084
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reactivity against the BP180 ectodomain in patients with bullous pemphigoid, mucous membrane pemphigoid, multiple sclerosis and Parkinson disease.
    Tegtmeyer J; Romagnuolo M; Hammers CM; Opelka B; Probst C; Komorowski L; Marzano AV; Schmidt E; Goletz S
    Exp Dermatol; 2024 Jul; 33(7):e15125. PubMed ID: 38946225
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IgG4 autoantibodies are inhibitory in the autoimmune disease bullous pemphigoid.
    Zuo Y; Evangelista F; Culton D; Guilabert A; Lin L; Li N; Diaz L; Liu Z
    J Autoimmun; 2016 Sep; 73():111-9. PubMed ID: 27377454
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IgE autoantibodies against the intracellular domain of BP180.
    Dresow SK; Sitaru C; Recke A; Oostingh GJ; Zillikens D; Gibbs BF
    Br J Dermatol; 2009 Feb; 160(2):429-32. PubMed ID: 18808416
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bullous pemphigoid of childhood: autoantibodies target the same epitopes within the NC16A domain of BP180 as autoantibodies in bullous pemphigoid of adulthood.
    Chimanovitch I; Hamm H; Georgi M; Kroiss M; Stolz W; Apitz C; Bröcker EB; Zillikens D
    Arch Dermatol; 2000 Apr; 136(4):527-32. PubMed ID: 10768652
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of a BP180-NC16a enzyme-linked immunosorbent assay in the initial diagnosis of bullous pemphigoid.
    Sakuma-Oyama Y; Powell AM; Oyama N; Albert S; Bhogal BS; Black MM
    Br J Dermatol; 2004 Jul; 151(1):126-31. PubMed ID: 15270881
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Missing the target: characterization of bullous pemphigoid patients who are negative using the BP180 enzyme-linked immunosorbant assay.
    Fairley JA; Bream M; Fullenkamp C; Syrbu S; Chen M; Messingham KN
    J Am Acad Dermatol; 2013 Mar; 68(3):395-403. PubMed ID: 23083837
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.